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The TM6SF2 E167K genetic variant 
induces lipid biosynthesis and 
reduces apolipoprotein B secretion 
in human hepatic 3D spheroids
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Raffaela Rametta3, Kajsa P. Kanebratt1, Arturo Pujia4, Piero Pingitore2,  
Rosellina Margherita Mancina  2, Daniel Lindén5,6, Carl Whatling7, Annika Janefeldt  1, 
Mikael Kozyra8, Magnus Ingelman-Sundberg  8, Luca Valenti3, Tommy B. Andersson1,8 & 
Stefano Romeo  2,4,9
There is a high unmet need for developing treatments for nonalcoholic fatty liver disease (NAFLD), for 
which there are no approved drugs today. Here, we used a human in vitro disease model to understand 
mechanisms linked to genetic risk variants associated with NAFLD. The model is based on 3D spheroids 
from primary human hepatocytes from five different donors. Across these donors, we observed highly 
reproducible differences in the extent of steatosis induction, demonstrating that inter-donor variability 
is reflected in the in vitro model. Importantly, our data indicates that the genetic variant TM6SF2 
E167K, previously associated with increased risk for NAFLD, induces increased hepatocyte fat content 
by reducing APOB particle secretion. Finally, differences in gene expression pathways involved in 
cholesterol, fatty acid and glucose metabolism between wild type and TM6SF2 E167K mutation carriers 
(N = 125) were confirmed in the in vitro model. Our data suggest that the 3D in vitro spheroids can be 
used to investigate the mechanisms underlying the association of human genetic variants associated 
with NAFLD. This model may also be suitable to discover new treatments against NAFLD.
Nonalcoholic fatty liver disease (NAFLD) is considered a global epidemic1 and the most common cause of 
chronic liver disease worldwide, with increasing prevalence2,3. It comprises a range of conditions, from rela-
tively benign simple steatosis to more progressed forms, including nonalcoholic steatohepatitis (NASH) and 
liver fibrosis which may progress to cirrhosis and hepatocellular carcinoma4–6 as well as cardiovascular morbidi-
ties7,8. NAFLD has a strong genetic component9, with the patatin-like phospholipase domain containing 3 I148M 
(rs738409, PNPLA3 I148M) and transmembrane 6 superfamily member 2 E167K (rs58542926, TM6SF2 E167K) 
genetic variants having the largest effect on the susceptibility to the entire spectrum of liver disease9.
Accumulation of intrahepatic fat is the hallmark of NAFLD. Despite a Mendelian Randomization study10 
suggesting a causal role of fat accumulation in causing liver fibrosis, the mechanism behind the toxicity of intra-
cellular neutral lipid is not clear. The increase in hepatocyte intracellular fat can be attributed to derangements of 
at least four main metabolic pathways: increased triglyceride (TG) synthesis, increased TG uptake, decreased fat 
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secretion or decreased fatty acid (FA) oxidation11. In genetic association studies carriers of the TM6SF2 E167K 
variant have substantially higher risk of NAFLD and at the same time lower risk for cardiovascular disease12–14. 
Human TM6SF2 E167K carriers have lower circulating apolipoprotein B100 (APOB) levels12,15 suggesting a 
reduction in the number of secreted lipoproteins. The TM6SF2 E167K genetic variant may result in a misfolded 
protein that is prone to intracellular degradation resulting in reduced protein levels13,16. Tm6sf2 inactivation in 
mice is, like in humans, associated with hypocholesterolemia and increased liver fat accumulation. In addition, 
hepatic VLDL-TG secretion rate is reduced while the APOB secretion is unaffected in the Tm6sf2 knock-out (KO) 
mice, indicating no change in the number of secreted lipoprotein particles from the liver17 in discordance with 
the human data12,15.
At present, there is no effective and approved pharmacotherapy available for the treatment of NAFLD. For 
development efforts aiming at novel treatments, disease models reflecting human NAFLD are required. Numerous 
dietary and genetic animal models are used for investigating the disease and its progression, of which most are 
rodent models18,19. The indisputable advantage of in vivo models is the representation of the (patho)physiolog-
ical interplay of organs in the body. However, animal models have also clear limitations such as interspecies 
differences across liver pathways20,21, disease characteristics21,22, high costs and ethical concerns. Thus, human in 
vitro systems are commonly used to complement animal experimentation23. To address the limitations of simple 
human in vitro models culturing primary hepatocytes in a classical 2D monolayer, 3D spheroids generated from 
primary human hepatocytes have proven to be excellent surrogates for human physiology24 by providing an in 
vivo-like cellular microenvironment24,25. However, spheroids composed of primary human hepatocytes have not 
been exploited as a model to investigate molecular genetic mechanisms involved in the development of NAFLD.
Aim of this work was to generate a 3D spheroid model to study molecular genetics of NAFLD. To achieve 
this goal we first examined differences in hepatic lipid metabolism between wild type (WT) and carriers of the 
TM6SF2 E167K genetic variant using human data from hepatic transcriptome. Next, we used a recent in vitro 3D 
spheroid NAFLD model from primary human hepatocytes26. This in vitro system reflects the liver physiology of 
WT and TM6SF2 E167K donors.
Results
Enrichment analyses between TM6SF2 wild type and TM6SF2 E167K (rs58542926) mutant carri-
ers. We examined liver-derived RNA-Seq data from 125 patients at risk for NAFLD diagnosed by liver biopsies 
(Supplementary Tables S1 and S2). Among these, 116 were wild type (WT) and 9 were E167K mutant carriers. Since 
DESeq2 analysis did not show any differentially expressed gene, we hypothesized that the insignificant adjusted 
p-values are the direct consequence of low number of heterozygous carriers of the TM6SF2 E167K mutation (N = 9) 
compared to WT (N = 116). Therefore, to understand the metabolic changes in TM6SF2 E167K carriers, we per-
formed enrichment for genes with a nominal p-value < 0.05 which are related to hepatic glucose and lipid metab-
olism using Gene Ontology (GO) biological process (BP) terms and KEGG biological pathways (Supplementary 
Table S4). The most enriched GO terms and KEGG pathways were those related to cholesterol (cholesterol - 
GO:0006695 and sterol biosynthetic - GO:0016126 processes in GO-BP, and terpenoid backbone biosynthesis in 
KEGG), TG (GO:0006641) and FA metabolism (GO:0019217). Interestingly, KEGG pathways associated with viral 
hepatitis (Hepatitis C and B) and NAFLD were significantly enriched in our list of examined genes.
Spheroid morphology. Next, we generated a 3D spheroid model from primary human hepatocytes obtained 
from five individual donors, of which two were heterozygous for the TM6SF2 E167K allele, and three were WT. To 
avoid confounders, we refrained from using primary human hepatocytes carrying the PNPLA3 rs738409 variant 
(encoding for an isoleucine to methionine substitution at position 148 of the PNPLA3 protein, I148M), the strong-
est common genetic variant increasing liver fat content27. Furthermore, donors were genotyped for the PNPLA3 
rs2294918 (E434K), GCKR rs1260326 (P446L) and MBOAT7 rs641738 (C > T) NAFLD risk alleles (Supplementary 
Table S5). A total of 2,000 cryopreserved primary human hepatocytes from each of the five donors were seeded 
per well at day −7 (Fig. 1A). After one day cells started to aggregate, forming a 3D structure (Fig. 1B). After three 
days of culture the aggregates resulted in spheroidal structures (Fig. 1C), further condensing over the following 4 
days (Fig. 1D,E). During the spheroid formation the diameter of the entirety of seeded cells from the WT-1 donor 
decreased by approximately 45%, starting from a diameter of 450 µm (Supplementary Fig. S1). This formation pat-
tern was similar in all donors. At day 0 the spheroids were fully formed with intact and distinct borders (Fig. 1E).
Spheroids are viable and well differentiated up to 10 days with and without fatty acid incu-
bation. To generate a 3D spheroid hepatocyte model of NAFLD, we incubated spheroids with increasing 
amounts of 2:1 oleic:palmitic acid-enriched medium (160 µM, 240 µM (data not shown) and 320 µM total FA 
concentration, conjugated to bovine serum albumin (BSA), as described previously26. Medium was changed every 
two days with sampling of spheroids and medium supernatant as depicted in Fig. 1. To test whether FA incuba-
tion results in spheroid morphological changes we measured the size at treatment days two, four, six and ten. We 
found no differences in diameter across days and with different treatment concentrations of FAs (Supplementary 
Fig. S2). We also examined shape and spheroid borders, which remained spherical with intact and distinct bor-
ders throughout all treatment conditions and time points (Fig. 2, Supplementary Fig. S3).
To assess the viability of cultured spheroids, we determined intracellular ATP content after incubation with 
and without FAs using two different concentrations at treatment day two, four, six and ten (Fig. 3). We observed 
no differences in the ATP concentration among groups throughout treatment concentrations and time points.
Next, we evaluated differentiation of hepatocytes in spheroids by determining intracellular and extracellu-
lar levels of APOB, a protein only expressed in hepatocytes and involved in hepatocyte TG secretion by very 
low-density lipoprotein (VLDL), a pathway present exclusively in hepatocytes. We found that APOB protein 
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synthesis was preserved (Figs 4A and 7A,B) from beginning of treatment up to the end (10 days). Also, the syn-
thesized APOB was consistently secreted into the extracellular space up to the end of the treatment, as shown by 
protein levels in the medium (Figs 4B and 7A,B).
All these data suggest that spheroids are viable, well differentiated and functional up to 10 days of incubation 
with FAs.
FA incubation results effectively in intracellular neutral lipid accumulation. To test whether FA 
incubation results in an increased fat content in the spheroids, we measured total intracellular TG content in 
single cell suspension obtained from disintegrated spheroids by fluorescence intensity using AdipoRed™ assay 
reagent (Fig. 5A) and by confocal Nile Red imaging of fixed and morphologically intact spheroids after two, six 
(Supplementary Fig. S4) and 10 days (Fig. 5B) of FA incubation. We found an increase in the total amount of 
intracellular fat content after incubation with increasing amounts of FAs in all donors (Supplementary Fig. S5,) 
and with increasing duration of the incubation (Supplementary Fig. S6). Incubation with an intermediate con-
centration of FA (240 µM; 160 µM OA/80 µM PA) led to an intermediate treatment response lying between the 
ones of low and high FA concentration (data not shown). Overall, the TM6SF2 E167K-1 and -2 donors had higher 
intracellular lipids from day four to the end of the incubation.
Importantly, donor-specific patterns in fat accumulation were robustly confirmed during one repeat exper-
iment for donors TM6SF2 E167K-2, WT-1 and WT-2, using low and high FA concentrations (Supplementary 
Fig. S7).
RNA measurement of key metabolic genes from human genetic analyses. Next, to compare the 
in vitro results with our ex vivo data in human liver, we measured the gene expression levels of the enzymes in 
the cholesterol, FA metabolism and gluconeogenesis pathway that were significantly differentially expressed in 
humans carrying the TM6SF2 mutant protein, both in spheroids carrying the TM6SF2 E167K and WT allele. 
We compared the expression levels in TM6SF2 E167K (pooled from 2 donors) and WT (pooled from 3 donors) 
spheroids after 2 days of incubation with high FA concentration (320 µM total FA, 213 µM OA/107 µM PA), and 
examined the directional regulation (up or down) of these genes (Supplementary Table S3).
Consistent with the human ex vivo data, genes related to cholesterol biosynthesis (FDPS, HMGCS1, FDFT1, 
DHCR7 and SC5D), de novo lipogenesis (FASN and ACSS2) and phospholipid dephosphorylation (PLPP3) were 
upregulated in the hepatic TM6SF2 E167K spheroids, while gluconeogenesis (FBP1) was upregulated in the sphe-
roids and downregulated in humans carrying the E167K risk variant (Fig. 6). ACADS, an enzyme involved in 
FA β-oxidation was upregulated in spheroids, but downregulated in human ex vivo data. PNPLA2, an enzyme 
involved in TG metabolism, was upregulated in spheroids, but downregulated in humans (Fig. 6).
Figure 1. Overview of spheroid generation and study design. Spheroids were generated by incubating 2000 
primary human hepatocytes for 7 days in 384- or 96-well ultra-low attachment plates. Initiation of spontaneous 
cell aggregation was observed within one day after seeding. Hepatocytes from five individual donors were used 
in two independent experiments for WT-1, WT-2 and TM6SF2 E67K-2, and in one independent experiment for 
WT-3 and TM6SF2 E167K-1, respectively (data from repeat experiments shown in Supplementary Fig. S7). For 
each experiment, an individual vial of cryopreserved primary hepatocytes was used for spheroid preparation. 
Bright-field images representatively show spheroid formation by spontaneous aggregation of hepatocytes 
obtained from donor WT-1. Hepatocytes from all other donors showed similar spheroid formation behavior, 
yielding fully formed spheroids after 7 days. Arrows in the timeline depict medium changes for incubation with 
FA and samplings for bright field (Figs 2A–C and S3) and confocal (Figs 5B and S4) imaging, intracellular ATP 
content (Fig. 3), intracellular and secreted APOB (Figs 4 and 7A,B), intracellular total TG content (Fig. 5A) 
and gene expression profiling (Figs 6 and 7C), respectively. Bars = 200 µm. Abbreviations: ATP, adenosine 
triphosphate; APOB, APOLIPOPROTEINB100; FA, fatty acid; TG, triglyceride, WT, wild type.
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Spheroids carrying the TM6SF2 E167K variant have lower APOB secretion. To understand the 
consequences of carriage of the TM6SF2 E167K variant, we examined the relative difference in APOB levels in 
the medium supernatant from spheroids of the donors. Medium obtained from TM6SF2 E167K spheroids con-
tained lower levels of APOB (Fig. 7A,B). Since there is one APOB protein per secreted VLDL particle28, these data 
indicate that hepatocyte spheroids from TM6SF2 E167K carriers secrete fewer APOB VLDL particles compared 
to WT spheroids. To further understand whether the reduction in the APOB was due to changes in APOB expres-
sion we examined mRNA levels of APOB at day 2 of incubation with FAs in spheroids from both types of donors. 
We observed a reduction of mRNA levels in four out of the five donors, where the donors carrying the TM6SF2 
E167K protein had a slightly lower reduction (−0.15 fold, TM6SF2 E167K-1 and −0.79 fold, TM6SF2 E167K-2) 
Figure 2. Spheroids show no morphological changes for up to 10 days of FA treatment. Bright-field images of 
spheroids from the TM6SF2 E167K-2 (A), WT-1 (B) and WT-2 (C) donor, without (top row, Control, FA-free 
BSA) and with FA treatment (bottom row, high FA, BSA + 213 µM OA/107 µM PA) for up to 10 days showed 
no morphological differences between the two populations. Corresponding bright-field images of the TM6SF2 
E167K-1 and WT-3 donors are shown in Supplementary Fig. S3. Bar = 200 µm. Abbreviations: BSA, bovine 
serum albumin; FA, fatty acid; OA, oleic acid; PA, palmitic acid; WT, wild type.
5Scientific RepoRtS |         (2019) 9:11585  | https://doi.org/10.1038/s41598-019-47737-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 3. Spheroid viability is not compromised by FA treatment. Total intracellular ATP content measured by 
luminescence using CellTiter-Glo® 3D Cell Viability Assay (Promega) in primary human hepatocyte spheroids 
with and without FA treatment for up to 10 days, using control (FA-free BSA) and two FA concentrations (low 
FA, BSA + 107 µM OA/53 µM PA and high FA, BSA + 213 µM OA/107 µM PA). Spheroids were generated from 
hepatocytes derived from five individual donors, out of which two were mutant and three were wild type for 
TM6SF2 E167K. Data are mean ± SD of eight single spheroid replicates per time point and condition and from 
one spheroid preparation per donor. Abbreviations: ATP, adenosine triphosphate; BSA, bovine serum albumin; 
FA, fatty acid; OA, oleic acid; PA, palmitic acid.
Figure 4. Spheroids are well-differentiated for up to 10 days of fatty acid incubation. Intracelluar (A) and 
extracellular (B) APOB protein levels in spheroids and culture medium, respectively, up to 10 days of FA 
incubation. APOB was measured by immunoblotting analysis, using anti-APOB and anti-calnexin (CNX) 
antibodies, from cell lysate and medium supernatant of primary human hepatocyte spheroids that were derived 
from three individual donors. APOB levels were assessed with low (BSA + 107 µM OA/53 µM PA), high 
(BSA + 213 µM OA/107 µM PA) and without (FA-free BSA) incubation with FAs. Original, uncropped blots 
are presented in Supplementary Fig. S8. This figure shows data from of one independent experiment per donor. 
Abbreviations: Ab’, antibody; APOB, APOLIPOPROTEINB100; BSA, bovine serum albumin; CNX, Calnexin; 
FA, fatty acid.
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Figure 5. Spheroids accumulate intracellular neutral triglycerides upon incubation with fatty acids. Spheroids 
were incubated with a 2:1 mixture of OA and PA (conjugated to BSA), for up to 10 days. Exposure was conducted 
using low (BSA + 107 µM OA/53 µM PA) and high (BSA + 213 µM OA/107 µM PA) FA concentration, as well 
as FA-free BSA (control). (A) Total TG content of liver spheroids, measured by fluorescence intensity using 
AdipoRed™ Assay Reagent. Spheroids were formed using primary human hepatocytes derived from five 
individual donors, out of which two were mutant (TM6SF2 E167K-1, TM6SF2 E167K-2) and three were wild type 
(WT-1, WT-2, WT-3) for TM6SF2 E167K. TG content is shown as fold change relative to vehicle control (FA-free 
BSA). Data represent mean values ± SD from 16 individual spheroid replicates per time point and condition, from 
one spheroid preparation per donor (repeat experiments of the donors TM6SF2 E167K-2, WT-1, and WT-2 are 
shown in Supplementary Fig. S7). (B) Nile red staining of low FA and high FA-incubated liver spheroids derived 
from three individual hepatocyte donors, after 10 days of FA incubation. Bars = 50 µm. Abbreviations: BSA, bovine 
serum albumin; FA, fatty acid; OA, oleic acid; PA, palmitic acid; TG, triglyceride.
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than the WT-1 (−1.87 fold) and WT-2 donor (−2.56 fold). APOB expression in WT-3 was unchanged (Fig. 7C). 
We also did not observe any difference in APOB expression, nor in the expression of microsomal triglyceride 
transfer protein (MTTP), a protein necessary for the assembly of APOB-containing lipoproteins, in the transcrip-
tome of patients at risk for NAFLD carrying the TM6SF2 E167K protein.
Discussion
In this work we show in both human liver tissue samples and in 3D spheroid cultures of primary human hepato-
cytes that carriage of the TM6SF2 E167K mutant protein is associated with an upregulation of the cholesterol and 
FA biosynthesis pathways. We also demonstrate that spheroid cultures with human primary hepatocytes obtained 
from two TM6SF2 E167K donors have lower secretion of APOB compared to spheroids formed from hepatocytes 
of three wild type (WT) hepatocyte donors investigated.
We started by examining enrichment for significantly differentially expressed genes (by GO and KEGG path-
ways analyses) in human liver from individuals at risk for liver disease carrying the TM6SF2 E167K sequence var-
iant, as compared to the WT. We found a striking upregulation of most of the enzymes involved in lipid synthesis 
and specifically of cholesterol and FA metabolism with both GO and KEGG. Interestingly, KEGG analyses found 
an enrichment of genes which are classified as involved in the pathogenesis of viral hepatitis and NAFLD. This is 
in line with the human genetic association data showing that TM6SF2 E167K carriers have higher risk not only 
for NAFLD but also for progression of liver damage in patients infected by viral hepatitis B and C29,30.
Next, we used a novel 3D spheroid NAFLD model utilizing primary human hepatocytes24 from five individual 
donors, two carrying the TM6SF2 E167K protein and three the WT protein. In both TM6SF2 E167K and WT the 
ATP levels, as well as APOB synthesis and secretion were preserved up to ten days after formation, indicating that 
spheroids were viable, well differentiated and functional within this time frame. Next, to induce intracellular lipid 
accumulation, we exposed the spheroids to increasing doses of a mixture of saturated and monounsaturated FAs 
for up to 10 days. FA load did not affect spheroid viability and differentiation. Most importantly, in the spheroids 
derived from the TM6SF2 E167K donor we consistently found a larger increase in the intracellular fat content 
as compared to the WTs, which was dose- and time-dependent. This suggests that the spheroids may represent 
a reliable model to study the mechanism underpinning predisposition to lipid accumulation in carriers of the 
TM6SF2 E167K variant. Furthermore, the phenotypic expression of the mutation in the presence of excess FAs is 
consistent with the recent gene environment interaction observed for this gene variant31.
We examined the intracellular biological pathways by differential expression analysis and found that, consist-
ent with human data, TM6SF2 E167K spheroids had upregulated genes involved in the cholesterol, FA and glu-
cose metabolism. Overall, the directional regulation of genes involved in cholesterol metabolism was consistent 
in humans and the spheroid model. We found a discordance in enzymes involved in lipolysis (PNPLA2), gluco-
neogenesis (FBP1) and β-oxidation (ACADS). While PNPLA2 is a key enzyme in lipolysis, we did not observe 
any significant change in the expression of other lipolytic enzymes (LIPE and MGLL) involved in TG hydrolysis 
in humans.
Figure 6. Transcriptional data derived from human liver and primary human hepatocyte spheroids show 
consistent changes in metabolic pathways when the TM6SF2 E167K variant is carried. Genes related to 
cholesterol biosynthesis, de novo lipogenisis and phospholipid dephosphorylation were upregulated both 
in human livers and spheroids carrying the rs58542926 risk variant and exposed for 2 days to high FA 
concentration (BSA + 213 µM OA/107 µM PA). To be comparable to RNA-Seq analysis, the regulation of key 
genes examined in RT-PCR were evaluated relative to FA-treated versus FA-free BSA control samples for both 
TM6SF2 E167K and WT. The reported values are the log2 normalized fold changes (log2 FCMUT/FCWT). Error 
bars represent the standard error of the mean (SEM) from the two TM6SF2 E167K carriers and the three WTs. 
Genes involved in Gluconeogenisis (FBP1), FA β-oxidation (ACADS), and TG metabolism (PNPLA2) where 
differentially regulated in humans and spheroids carrying the TM6SF2 E167K risk variant.
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Taken all this together, our data indicate that the spheroids generated from TM6SF2 E167K primary hepat-
ocytes have similar metabolic changes present as in livers of human carriers. These changes, namely increased 
cholesterol and FA biosynthesis, may contribute to the increase in intracellular fat. Interestingly, excess in free 
cholesterol is known to cause hepatic damage32,33. Our data are consistent with increased cholesterol esters in 
the liver of TM6SF2 E167K carriers34. Therefore, although we could not evaluate protein expression and directly 
measure de novo lipid synthesis, our data suggest that the progression of NAFLD in TM6SF2 E167K carriers could 
be ascribed not only to reduced lipid secretion13, but also to the excess synthesis of cholesterol or other lipotoxic 
lipid species32,33. Interestingly, the mouse knockout (KO) model and in vitro overexpression of the TM6SF2 E167K 
sequence variant accumulates intrahepatic fat, but this was associated with reduced cholesterol biosynthesis17,35, 
possibly suggesting that the mouse model may not closely mirror human physiology. However, in contrast to 
our results, a previous study reported downregulation of lipid synthesis in the liver of TM6SF2 E167K carriers34.
Next, to investigate on the mechanism of intracellular fat retention we examined the APOB secretion as well 
as intracellular synthesis in spheroids. We found that TM6SF2 E167K spheroids show a lower secretion of APOB, 
coupled to lower intracellular APOB protein levels. The Tm6sf2 KO mouse was found to have unchanged secre-
tion of APOB particle number17, while a human genetic association study showed lower levels of circulating 
APOB15. Our data are consistent with the human genetic association study, indicating a defect in secretion of 
APOB particles, which may cause intracellular lipid increase. Regarding the cause of reduction in APOB secre-
tion, we found lower intracellular levels of APOB. This could be due to an increase in APOB degradation, possibly 
due to unlipidated or underlipidated forms of APOB36. These data are consistent with the notion that decreased 
transfer of FAs on nascent VLDL in the endoplasmic reticulum (lipidation) contributes to intrahepatic fat accu-
mulation in TM6SF2 E167K carriers17. However, differently than in the mice model, we showed that in human 
Figure 7. Liver spheroids derived from the TM6SF2 E167K donors show substantially decreased synthesis and 
secretion of APOB as compared to spheroids derived from the WT donors. (A) Immunoblots using anti-APOB 
and anti-calnexin (CNX) antibodies comparing APOB synthesis (lysate) and secretion (medium) in WT-1, 
TM6SF2 E167K-2 and WT-2 show decreased APOB particle number intracellularly and in medium samples 
obtained from the TM6SF2 E167K-2 donor after incubation with high FA (BSA + 213 µM OA/107 µM PA) 
for up to 10 days. Quantifications relative to WT-1 and WT-2 are shown below the cropped blots. Original, 
uncropped blots are provided in Supplementary Fig. S9A. (B) Immunoblot and quantifications layout as 
presented in (A), showing donor WT-3 vs. TM6SF2 E167K-1. Original, uncropped Blots are provided in 
Supplementary Fig. S9B. (C) Relative mRNA levels of APOB and MTTP (log2 transformed) after a 2-day 
incubation with high FA (BSA + 213 µM OA/107 µM PA), normalized to GAPDH and expressed relative to 
the levels of FA-free BSA treated control. APOB and MTTP are slightly downregulated in spheroids derived 
from the TM6SF2 E167K donors, while the WT-1 and WT-2 donors show a stronger downregulation of 
APOB and MTTP. In WT-3, APOB expression was unchanged and MTTP slightly downregulated. The 
figure represents data from one experiment per donor and RNA was extracted from 20 pooled spheroids per 
donor. Abbreviations: Ab’, antibody; APOB, APOLIPOPROTEINB100; CNX, calnexin; FA, fatty acid; MTTP, 
microsomal triglyceride transfer protein; OA, oleic acid; PA, palmitic acid.
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hepatocytes this defect also results in decreased APOB protein levels and secretion. A limitation of our study is 
that we cannot take into account the effect of intestinal uptake of lipids in chylomicrons which is also reduced 
in the presence of the TM6SF2 mutant protein in the postprandial state37. However, the data presented in this 
study and in previous genetic studies were in a fasting state, minimizing the interference of lipoproteins of the 
fed state12,15.
The main limitation of our study is that the number of mutant donors was limited and therefore the results 
should be interpreted with caution. In our screening efforts, it was not possible to identify further TM6SF2 E167K 
hepatocyte donors because of the relatively low allele frequency of this sequence variant. It should also be taken 
into consideration that the two mutant donors were of younger age (13 and 22 years, Supplementary Table S5) 
as compared to the three wild type donors (30, 44 and 78 years, Supplementary Table S5), which could influence 
hepatocyte function.
In conclusion, we showed a lower APOB secretion in primary human hepatocyte spheroids from TM6SF2 
E167K as compared with WT, while the cholesterol biosynthesis was higher in the TM6SF2 E167K spheroids 
when exposed to FAs. These data, generated in an experimentally accessible in vitro setting, recapitulate the dif-
ferences found in human WT and TM6SF2 E167K carriers. Hence, 3D spheroids may represent a useful model to 
study mechanism of NAFLD development and impact of genetic background, offering a promising tool for drug 
development.
Materials and Methods
Materials. Unless stated otherwise, medium supplements and reagents were obtained from Sigma-Aldrich 
(Stockholm, Sweden) and LifeTechnologies (Stockholm, Sweden).
Patient cohort, RNA seq and statistical analyses. RNASeq was performed in 125 severely obese 
individuals who underwent to percutaneous liver biopsy performed during bariatric surgery, as described in 
a previous study assessing the role of a genetic variant in the protein phosphatase 1 regulatory subunit 3B gene 
(PPP1R3B)38. Informed consent was obtained from each patient and the study protocol was approved by the 
Ethical Committee of the Fondazione IRCCS Ca’ Granda, Milan and conformed to the ethical guidelines of the 
1975 Declaration of Helsinki. Individuals with increased alcohol intake (men: >30 g/day; women: >20 g/day), 
viral and autoimmune hepatitis or other causes of liver disease were excluded. Steatosis was graded based on 
the percentage of affected hepatocytes as 0: 0–4%, 1: 5–32%, 2: 33–65%, and 3: 66–100%. NAFLD Activity Score 
(NAS) was assessed by systematic evaluation of hepatocellular ballooning and necroinflammation. Fibrosis was 
also staged according to the recommendations of the NAFLD clinical research network39.
RNA extraction was performed using miRNeasy mini-kit (Qiagen, Hilden, Germany), according to the man-
ufacturer’s instructions. Agilent 2100 Bioanalyzer was used for RNA qualitative assessment, high-quality samples 
(RNA integrity number >7) were used for library preparation. RNA was sequenced in paired-end mode using 
an Illumina HiSeq 4000 (Novogene, Hong Kong, China). Reads quality evaluation and trimming was conducted 
using FastQC (Babraham Bioinformatics, Cambridge, UK) and Trimmomatic40 packages. Reads were mapped 
against GRCh37 reference genome41 using STAR aligner42. Samples with insufficient mapping quality (<10 mil-
lion mapped reads, uniquely mapped <60% mapped reads) were excluded. Per gene reads were counted accord-
ing to the ENSEMBL human transcript reference assembly version 75 exploiting RSEM package43. Raw counts 
normalization and differential gene expression analysis were performed exploiting DESeq2 package44 according 
to the standard workflow. P-values were corrected for testing multiplicity by Benjamini-Hochberg false discovery 
rate45.
Gene Ontology (GO) and pathway enrichment analysis. We used GeneTrail2 tool (26787660) to test 
for the enrichment of functional annotations among differentially expressed genes between TM6SF2 rs58542926 
wild type and E167K mutant carriers (nominal p-value < 0.05). The tests were carried out using Gene Ontology 
(GO) Biological Processes (BP) and KEGG pathways. Hypergeometric distribution was used to calculate p-values, 
which were subsequently adjusted for multiple hypothesis testing using Benjamini and Hochberg false discovery 
rate (FDR) correction45.
3D liver spheroids formation and maintenance. All cryopreserved primary human hepatocytes used 
in this study were obtained from BioIVT (Brussels, Belgium) and thawed according to the supplier’s instructions. 
It was not possible to identify additional TM6SF2 E167K donors. The sourcing details and demographics of the 
donors are available in Supplementary Table S5. For spheroid formation, the methods described in Bell et al.24 and 
Kozyra et al.26 were mainly employed, using slight variations. In short, 2,000 viable cells per well were seeded into 
ultra-low adhesion 384-well plates (3830 Corning, Corning, NY, USA) or ultra-low adhesion 96-well plates (7007 
Corning, Corning, NY, USA). Total viabilities of the cell preparations after thawing ranged between 90–95% 
for hepatocytes from all donors, except for the TM6SF2 E167K-1 donor (84%). Since lower total cell viability is 
frequently associated with reduced spheroid formation capability, brief exposure to the pan-caspase apoptosis 
inhibitor Z-VAD-FMK was used to support spheroid formation, as described recently46. The same treatment 
was done for the WT-3 donor to allow for direct comparisons of both preparations (Fig. 7B). After seeding, the 
plates were centrifuged at 100 × g for 2 min. Cells were seeded in Williams E medium (PAN-Biotech, Aidenbach, 
Germany), supplemented with 5.5 mM glucose, 2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml strepto-
mycin, 100 pM insulin, 5.5 µg/ml transferrin, 6.7 ng/ml sodium selenite, 100 nM dexamethasone and 10% fetal 
bovine serum. The cells were allowed to aggregate and form spheroids for 7 days, with daily medium change 
starting on the fourth day of culture. Medium changes were performed with FBS-free medium of the otherwise 
same formulation as described above (maintenance medium). After the start of fatty acid incubation, medium 
was changed every 48 hours (Fig. 1).
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Steatosis induction. Hepatic steatosis was induced by metabolic stimulation with the unsaturated FA oleic 
acid (OA) and the saturated FA palmitic acid (PA) in a ratio of 2:1, mimicking human plasma concentrations 
of free fatty acids (FFAs), as described previously26. Exposure started 7 days after seeding (regarded as day 0, cf. 
Fig. 1). FAs were complexed to bovine serum albumin (BSA) for facilitating FFA uptake by the hepatic spheroids. 
In short, complexing was achieved by incubating the FAs with 10% BSA (wt/vol, FA-free) in a molar ratio of 1:5 
at 40 °C for 2 hours. All complexed solutions were sterile filtered. The OA/PA complex was added to maintenance 
medium (described above) for two final total FA concentrations: low, 160 µM (107 µM OA/53 µM PA) and high, 
320 µM (213 µM OA/107 µM PA). Controls were supplemented with FA-free BSA in equimolar concentrations as 
used in high FA incubation.
Adenosine triphosphate content. Total intracellular adenosine triphosphate (ATP) content was quanti-
fied by luminescence using CellTiter-Glo® 3D Cell Viability Assay (Promega, Madison, WI, USA) with a slightly 
modified protocol. In brief, for each replicate one individual spheroid was transferred by sedimentation into a 
white 96-well assay plate (3903 Corning, Corning, NY, USA) containing 50 µl PBS (w/o Mg2+, Ca2+) per well. 
Subsequently, 50 µl of assay reagent were added following vigorous mixing for further promoting penetration of 
the 3D reagent into the spheroid matrix. The plate was incubated in the dark for 25 min at room temperature and 
luminescence was read using a SpectraMax Gemini XS (Molecular Devices, San Jose, CA, USA) reader.
Triglyceride imaging. Intracellular neutral lipid droplets were stained using Nile Red staining, nuclei were 
stained using Hoechst 33342 (Invitrogen, Carlsbad, CA). In brief, a double-staining solution containing 2 µM Nile 
Red and 16 µM Hoechst 33342 was prepared in PBS (w/o Mg2+, Ca2+). Prior to staining, spheroids were fixed in 
a 4% paraformaldehyde solution at room temperature for 1 hour, followed by storage at 4 °C in PBS (w/o Mg2+, 
Ca2+). Fixed spheroids were incubated with double-staining solution at room temperature for 90 min, followed 
by incubation at 37 °C for 30 min and washing with PBS (w/o Mg2+, Ca2+). Confocal imaging was performed in a 
black 96-well assay plate (353219 Corning, Corning, NY, USA) using an LSM880 Airyscan (Zeiss, Jena, Germany) 
microscope.
Intracellular triglyceride quantification. Intracellular TG content was determined using a fluorescent 
probe that specifically partitions into fat droplets (AdipoRed, Lonza, Switzerland), following the manufacturer’s 
instructions with slight modifications. For facilitating access of the reagent to all cells, the spheroids were disin-
tegrated using trypsin treatment. Trypsin solution was prepared by a 1:1 dilution 0.5% trypsin-EDTA with PBS 
(w/o Mg2+, Ca2+), of which 200 µl were used per assay in a black 96-well assay plate (3631 Corning, Corning, NY, 
USA). For each spheroid replicate (total of 16 per time point), one individual spheroid was taken up in 20 µl of its 
maintenance or treatment medium, respectively, and the complete volume transferred into the trypsin solution. 
For determining the culture medium-derived background signal, for each replicate (total of eight per time point) 
20 µl of maintenance or treatment medium supernatant, respectively, without spheroid were added to the trypsin 
solution. The fully prepared assay plate was incubated at 37 °C for 10 min. Following, 7 µl of AdipoRed reagent was 
added to each replicate of spheroid sample and culture medium background assay, respectively. For full dissoci-
ation of the 3D spheroid cell aggregates, repeated and vigorous resuspending of the suspension was performed. 
Subsequently, the assay plate was incubated in the dark at room temperature for 10 min and fluorescence intensity 
was measured (ex: 485 nm, em: 572 nm) on an infinite 200 reader (Tecan, Männedorf, Switzerland). The culture 
medium-derived signal for each condition was subtracted from all respective spheroid samples prior to deter-
mining the relative fold change of fluorescence signal intensity between FA-free BSA control and FA-incubated 
conditions.
Intracellular protein isolation. For protein isolation, spheroids were pooled and washed twice with PBS 
(w/o Mg2+, Ca2+). Cell lysis was accomplished by repeated vigorous resuspension of the spheroids at 4 °C in a 
mixture of M-PER Mammalian Protein Extraction Reagent (Thermo Scientific, Rockford, IL, USA) and cOm-
pleteTM Mini Protease Inhibitor (Roche, Mannheim, Germany) working solution (prepared according to the 
manufacturer’s instructions), in a ratio of 9:1. The homogenate was sonicated 5 times for 15 s in ice cold water 
and subsequently centrifuged at 12000 × g and 4 °C for 15 min. The supernatant was extracted and total protein 
concentration determined on a Nanodrop 1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, 
USA). Samples were stored at −80 °C until further analysis.
Immunoblotting for APOB detection. Cell media samples were concentrated 10 times using Vivaspin 
500 columns (Sartorius Stedim Lab Ltd, Stonehouse, UK) for the APOB-100 detection. Cell lysates as well as con-
centrated and diluted cell media samples were mixed with Laemmli buffer containing 2-mercaptoethanol (ratio 
sample: Laemmli buffer = 4:1 v/v) and incubated for 5 min at 95 °C. Proteins were size-separated by SDS-page 
(6% acrylamide gel, 90 V, 3 h at 4 °C for APOB-100 and calnexin detection; 10% acrylamide gel, 130 V, 1 h at 
room temperature for albumin detection) and transferred onto a nitrocellulose membrane (0.2 A, 2.5 h at 4 °C). 
Nitrocellulose membranes were incubated overnight with primary antibodies, washed 3 times for 10 min with 
tris-buffered saline containing 0.2% tween (0.2% TBS-T buffer), incubated 1 h with HRP-conjugated second-
ary antibodies, washed 3 times for 10 min with 0.2% TBS-T buffer, incubated with Immobilon Western chemi-
luminescent HRP substrate (Millipore Corporation, Billerica, Massachusetts, USA). Bands were visualized 
using Chemidoc XRS System (Biorad, Hercules, California, USA). The following antibodies were used: mouse 
anti-APOB (Santa Cruz Biotechnology, Dallas, Texas, USA), rabbit anti-calnexin (Sigma-Aldrich, Saint Louis, 
Missouri, USA), mouse anti-albumin (Sigma-Aldrich, Saint Louis, Missouri, USA).
Genotyping. DNA was extracted from hepatocytes using DNeasy Blood & Tissue Kit (Qiagen, Hilden, 
Germany). DNA from all donors was undergone to genotyping for TM6SF2_rs58542926 (E167K), PNPLA3 
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rs738409 (I148M), PNPLA3 rs2294918 (E434K), GCKR rs1260326 (P446L) and MBOAT7 rs641738 (C > T) 
polymorphisms by TaqMan™ assays (Life Technologies, Carlsbad, CA, USA) using CFX384 Real Time PCR 
detection system (Bio-Rad Laboratories, Hercules, CA, USA). Data analysis was performed using Bio-Rad CFX 
manager software.
Gene expression analysis. Total RNA was isolated using miRNeasy Mini Kit (Qiagen, Hilden, Germany). 
RNA was reverse-transcribed into cDNA using High Capacity cDNA Reverse Transcription (Applied Biosystems, 
Waltham, MA, USA). RT-qPCR analysis was performed on customized microfluidic TaqMan™ array 384-well 
cards using TaqMan™ Fast Advanced Master Mix (Applied Biosystems, Waltham, MA, USA) on a QuantStudioTM 
7 Flex Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). QuantStudioTM Real-Time PCR 
Software, version 1.3, (Applied Biosystems, Waltham, MA, USA) was used for data analysis.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
References
 1. Loomba, R. & Sanyal, A. J. The global NAFLD epidemic. Nature reviews. Gastroenterology & hepatology 10, 686–690, https://doi.
org/10.1038/nrgastro.2013.171 (2013).
 2. Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and 
outcomes. Hepatology 64, 73–84, https://doi.org/10.1002/hep.28431 (2016).
 3. Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States 
for the period 2016–2030. Journal of Hepatology 69, 896–904, https://doi.org/10.1016/j.jhep.2018.05.036 (2018).
 4. Ekstedt, M. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865–873, https://doi.
org/10.1002/hep.21327 (2006).
 5. Farrell, G. C. & Larter, C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99–s112, https://doi.
org/10.1002/hep.20973 (2006).
 6. Engin, A. In Obesity and Lipotoxicity (eds Ayse Basak Engin & Atilla Engin) 443–467 (Springer International Publishing, 2017).
 7. Francque, S. M., van der Graaff, D. & Kwanten, W. J. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological 
mechanisms and implications. J Hepatol 65, 425–443, https://doi.org/10.1016/j.jhep.2016.04.005 (2016).
 8. Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G. & Barbui, C. Non-alcoholic fatty liver disease and risk of incident cardiovascular 
disease: A meta-analysis. J Hepatol 65, 589–600, https://doi.org/10.1016/j.jhep.2016.05.013 (2016).
 9. Eslam, M., Valenti, L. & Romeo, S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol 68, 268–279, https://
doi.org/10.1016/j.jhep.2017.09.003 (2018).
 10. Dongiovanni, P. et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. Journal 
of internal medicine 283, 356–370, https://doi.org/10.1111/joim.12719 (2018).
 11. Kawano, Y. & Cohen, D. E. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. Journal of 
Gastroenterology 48, 434–441, https://doi.org/10.1007/s00535-013-0758-5 (2013).
 12. Dongiovanni, P. et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from 
cardiovascular disease. Hepatology 61, 506–514, https://doi.org/10.1002/hep.27490 (2015).
 13. Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver 
disease. Nat Genet 46, 352–356, https://doi.org/10.1038/ng.2901 (2014).
 14. Holmen, O. L. et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total 
cholesterol and myocardial infarction risk. Nat Genet 46, 345–351, https://doi.org/10.1038/ng.2926 (2014).
 15. Kim, D. S. et al. Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 
particles in Finns. Journal of lipid research 58, 1471–1481, https://doi.org/10.1194/jlr.P076034 (2017).
 16. Ehrhardt, N. et al. Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and 
atherosclerosis. Human molecular genetics 26, 2719–2731, https://doi.org/10.1093/hmg/ddx159 (2017).
 17. Smagris, E., Gilyard, S., BasuRay, S., Cohen, J. C. & Hobbs, H. H. Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, 
Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins. The Journal of biological chemistry 291, 10659–10676, 
https://doi.org/10.1074/jbc.M116.719955 (2016).
 18. Lau, J. K. C., Zhang, X. & Yu, J. Animal models of non‐alcoholic fatty liver disease: current perspectives and recent advances. The 
Journal of Pathology 241, 36–44, https://doi.org/10.1002/path.4829 (2017).
 19. Kanuri, G. & Bergheim, I. (2013).
 20. Lin, C., Ballinger, K. R. & Khetani, S. R. The application of engineered liver tissues for novel drug discovery. Expert Opinion on Drug 
Discovery 10, 519–540, https://doi.org/10.1517/17460441.2015.1032241 (2015).
 21. Hebbard, L. & George, J. Animal models of nonalcoholic fatty liver disease. Nature reviews. Gastroenterology & hepatology 8, 35–44, 
https://doi.org/10.1038/nrgastro.2010.191 (2011).
 22. McGonigle, P. & Ruggeri, B. Animal models of human disease: challenges in enabling translation. Biochemical pharmacology 87, 
162–171, https://doi.org/10.1016/j.bcp.2013.08.006 (2014).
 23. Ewart, L. et al. Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery. Annual review of 
pharmacology and toxicology 58, 65–82, https://doi.org/10.1146/annurev-pharmtox-010617-052722 (2018).
 24. Bell, C. C. et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver 
function and disease. Sci Rep 6, 25187, https://doi.org/10.1038/srep25187 (2016).
 25. Messner, S., Agarkova, I., Moritz, W. & Kelm, J. M. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol 
87, 209–213, https://doi.org/10.1007/s00204-012-0968-2 (2013).
 26. Kozyra, M. et al. Human hepatic 3D spheroids as a model for steatosis and insulin resistance. Scientific Reports 8, 14297, https://doi.
org/10.1038/s41598-018-32722-6 (2018).
 27. Pingitore, P. & Romeo, S. The role of PNPLA3 in health and disease. Biochimica et biophysica acta, https://doi.org/10.1016/j.
bbalip.2018.06.018 (2018).
 28. Walldius, G. & Jungner, I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for 
lipid-lowering therapy. European heart journal 26, 210–212, https://doi.org/10.1093/eurheartj/ehi077 (2005).
 29. Eslam, M. et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. 
Hepatology 64, 34–46, https://doi.org/10.1002/hep.28475 (2016).
 30. Liu, Z. et al. The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-
analysis. Sci Rep 7, 9273, https://doi.org/10.1038/s41598-017-09548-9 (2017).
 31. Stender, S. et al. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 49, 842–847, https://
doi.org/10.1038/ng.3855 (2017).
1 2Scientific RepoRtS |         (2019) 9:11585  | https://doi.org/10.1038/s41598-019-47737-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
 32. Ioannou, G. N. The Role of Cholesterol in the Pathogenesis of NASH. Trends in Endocrinology & Metabolism 27, 84–95, https://doi.
org/10.1016/j.tem.2015.11.008 (2016).
 33. Arguello, G., Balboa, E., Arrese, M. & Zanlungo, S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. 
Biochimica et biophysica acta 1852, 1765–1778, https://doi.org/10.1016/j.bbadis.2015.05.015 (2015).
 34. Luukkonen, P. K. et al. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with 
NAFLD. Journal of Hepatology 67, 128–136, https://doi.org/10.1016/j.jhep.2017.02.014 (2017).
 35. Fan, Y. et al. Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice. Gastroenterology 150, 
1208–1218, https://doi.org/10.1053/j.gastro.2016.01.005 (2016).
 36. Davidson, N. O., Shelness, G. S. & APOLIPOPROTEIN, B. mRNA editing, lipoprotein assembly, and presecretory degradation. 
Annual review of nutrition 20, 169–193, https://doi.org/10.1146/annurev.nutr.20.1.169 (2000).
 37. O’Hare, E. A. et al. TM6SF2 rs58542926 impacts lipid processing in liver and small intestine. Hepatology 65, 1526–1542, https://doi.
org/10.1002/hep.29021 (2017).
 38. Dongiovanni, P. et al. Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and 
fibrosis in individuals at high risk of nonalcoholic fatty liver disease. Hepatology Communications 2, 666–675, https://doi.
org/10.1002/hep4.1192 (2018).
 39. Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 
1313–1321, https://doi.org/10.1002/hep.20701 (2005).
 40. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics (Oxford, England) 
30, 2114–2120, https://doi.org/10.1093/bioinformatics/btu170 (2014).
 41. Zerbino, D. R. et al. Ensembl 2018. Nucleic acids research 46, D754–d761, https://doi.org/10.1093/nar/gkx1098 (2018).
 42. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics (Oxford, England) 29, 15–21, https://doi.org/10.1093/
bioinformatics/bts635 (2013).
 43. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC 
bioinformatics 12, 323, https://doi.org/10.1186/1471-2105-12-323 (2011).
 44. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome 
biology 15, 550, https://doi.org/10.1186/s13059-014-0550-8 (2014).
 45. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal 
of the Royal Statistical Society. Series B (Methodological) 57, 289–300 (1995).
 46. Ölander, M. et al. A simple approach for restoration of differentiation and function in cryopreserved human hepatocytes. Archives 
of Toxicology 93, 819–829, https://doi.org/10.1007/s00204-018-2375-9 (2019).
Acknowledgements
Sebastian Prill is a fellow of the AstraZeneca postdoc programme. This work was supported by the Swedish 
Research Council [Vetenskapsrådet (VR), 2015-02760 and 2016-01527], the Swedish Heart Lung Foundation 
[20120533], the ERC-AdG project HEPASPHER [742020], the Swedish federal government funding under the 
Agreement on Medical Training and Medical Research (ALF) [716731], the Novonordisk Foundation Grant for 
Excellence in Endocrinology [Excellence Project, 9321-430], the Swedish Diabetes Foundation [DIA 2017-205], 
a research grant from AstraZeneca [Echo Project, 10033852], Wallenberg Academy Fellows from the Knut and 
Alice Wallenberg Foundation [KAW 2017.0203] (SR), and the Wilhelm and Martina Lundgren Science Fund 
[2016-1255] (RMM). AIRC [MFAG N.16888], Italian Ministry of Health [RF-2016-02364358], Fondazione 
IRCCS Ca’ Granda - INGM Molecular Medicine Grant.
Author Contributions
S.P. designed and conducted experiments, analyzed and interpreted results, made all figures and drafted portions 
of the manuscript. A.C. conducted and analysed western blots, conducted genotyping experiments and reviewed 
and interpreted results. O.J. conducted the analysis and integration of transcriptomic data of the human cohort 
and 3D spheroids. G.B., P.D., R.R. and A.P. generated and analysed transcriptomic data of human liver samples. 
R.M.M. conducted genotyping work. P.P. conducted genotyping and cell experiments and interpreted results. 
A.J. conducted experiments and interpreted results, M.K. reviewed and interpreted results. K.K. supervised 
experiments and interpreted results. S.R. drafted portions of the manuscript. L.V. and M.I.S. reviewed and 
interpreted results and finalised the manuscript. S.R., T.B.A., K.K., C.W. and D.L. developed the study concept, 
reviewed and interpreted results and finalised the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-47737-w.
Competing Interests: Sebastian Prill, Kajsa P Kanebratt, Daniel Lindén, Carl Whatling, Annika Janefeldt and 
Tommy B Andersson are AstraZeneca employees. Magnus Ingelman-Sundberg is a co-founder of HepaPredict 
AB. Stefano Romeo has received consultancy fee and a grant from Astra Zeneca to study fatty liver disease.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
